• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sunshine Biopharma to conduct trial for Jewish General Hospital

Sunshine Biopharma to conduct trial for Jewish General Hospital

June 17, 2011
CenterWatch Staff

Sunshine Biopharma, a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary R&D to advance Sunshine's lead compound, Adva-27a, through the various stages of pre-clinical studies and phase I clinical trials.

Adva-27a is a small molecule that inhibits Topoisomerase II, an enzyme found in abundance in various types of aggressive cancer, and Adva-27a will be developed to target tumors with over-expression of this target.

Dr. Steve Slilaty, Sunshine's president and CEO, said, "We are very excited to work with the Segal Cancer Center of the Jewish General Hospital, one of the top cancer centers in North America.”

"We anticipate Adva-27a to be available for "compassionate-use" by the end of the trial, as small-cell lung cancer patients have limited treatment options at present,” he said. “We are excited by the prospects together with the long-standing history of the Jewish General to further enhance the length and quality of cancer patients in our community and throughout the world."

The pre-clinical and clinical studies will be under the directorship of Dr. Gerald Batist, M.D., Minda de Gunzburg Professor of Oncology and Director of the McGill University Center for Translational Research in Cancer, which is a comprehensive cancer research and treatment program that includes a Clinical Research Unit, a Tissue Repository, a Molecular Modeling Unit, a GMP Cell Preparation Facility and a virtual link-up of scientists throughout the Montreal area focusing on laboratory-clinic interface research.

Dr. Batist said, "After reviewing Sunshine's Adva-27a data we became very interested in advancing the development of this compound. We are always looking for new treatment options for our cancer patients... we are excited about the potential of Adva-27a as an active agent against an important and identifiable therapeutic target."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing